Tethis launches See.d®, the first fully automated, standardized pre-analytical platform for comprehensive liquid biopsy testing - Seite 2

SBS slides are compatible with all analytical pathology techniques, including
cytology, immunocytochemistry (ICC), Immunofluorescence (IF), Fluorescence in
Situ Hybridization (FISH), for morphological and biomarker-based analysis
through brightfield or fluorescence image acquisition. The extremely efficient
cell adhesion and the preserved morphology, together with the optimal
distribution of the cells on the slides as a monolayer, allows the
implementation of AI supported digital imaging for automated and efficient
detection, classification and profiling of rare circulating tumor cells as well
as of the immune cell compartment. Furthermore, identified cells can be
recovered through microdissection for downstream molecular analysis at single
cell level.

Plasma - on the other hand - is stable for several days with no need for
freezing and ready for cfNA extraction without any further centrifugation step.
The lean and automated processing provides uncontaminated, standardized plasma
for high quality, reproducible downstream analysis of cell-free content.

"We are thrilled to introduce this novel solution to the market" said Ms.
Roberta Carbone, Ph.D, Tethis' Chief Scientific Officer. "It's a first step
towards true multi-analytical, standardized liquid biopsy tests involving all
possible tumor content released in the bloodstream. We are now working on the
validation for CE-IVD marking of the platform and on the development of novel
liquid biopsy tests to bring to patients and at-risk individuals, but we also
welcome diagnostics industry players and drug developers who want to exploit the
optimal and comprehensive preparation guaranteed by See.d® for the development
of new tests and companion diagnostics or for patients' stratification in
clinical trials"

See.d® and SBS slides are for Research Use Only, not for use in diagnostic
procedures.

ABOUT TETHIS Tethis S.p.A is based in Milan, Italy, and is developing a novel
workflow to bring liquid biopsy in the clinical practice for the precise
management of cancer. Tethis' technology points to standardization of the blood
sample preparation to provide the highest quality and integrity of liquid biopsy
specimens for the comprehensive analysis of all clinically informative
biomarkers. The company's proprietary nanocoated slides combined with the
automated pre-analytical instrument allow to identify and characterize rare
cells in blood, like circulating tumor cells, with unprecedented sensitivity,
also in early-stage settings.

Further information is available on the company's website,
http://www.tethis-lab.com .

Photo - https://mma.prnewswire.com/media/1818232/Tethis_1.jpg

Logo - https://mma.prnewswire.com/media/1818233/Tethis_Logo.jpg

Contact:

[e-mail] / Mariagiulia Davide Phone Number: [phone]

Additional content: http://presseportal.de/pm/163134/5222809
OTS: Tethis S.p.A.